双歧杆菌三联活菌联合铋剂四联方案治疗消化性溃疡HP感染的疗效和安全性分析

Efficacy and safety of bifid-triple viable bacterial tablet combined with bismuth based quadruple therapy in treatment of peptic ulcer with HP infection

目的观察双歧杆菌三联活菌片与铋剂四联方案联合治疗消化性溃疡幽门螺杆菌(HP)感染的临床疗效及安全性。方法选取商丘市第一人民医院2015年1月—2017年1月收治的消化性溃疡HP感染患者100例,随机分为对照组及观察组,各50例。对照组采用铋剂四联方案治疗,观察组在对照组基础上加用双歧杆菌三联活菌片。比较两组疗效及安全性。结果观察组治疗总有效率、HP根除率均高于对照组,差异有统计学意义(P<0.05);观察组不良反应发生率低于对照组,差异有统计学意义(P<0.05)。结论对消化性溃疡HP感染患者使用双歧杆菌三联活菌片与铋剂四联方案联合治疗,患者HP有效根除,临床疗效显著,药不良反应少,用药安全性高。

Objective To observe the clinical efficacy and safety of bifid - triple viable bacterial tablet combined with bismuth based quadruple therapy in treatment of peptic ulcer with helicobacter pylori （HP） infection. Methods Totally 100 patients with peptic ulcer with of HP infection in our hospital from January 2015 to January 2017 were randomly divided into control group and observation group, 50 cases in each. Control group was treated with bismuth based quadrup- le therapy, observation group was treated with bifid - triple viable bacterial table based on control group. The efficacy and safety of two groups were compared. Results The total effective rate, the eradication rate of HP of observation group was higher than that of control group （ P 〈 0. 05 1 ; The incidence of adverse reactions of observation group was lower than that of control group （ P 〈 0. 05 ）. Conclusion Bifid - triple viable bacterial tablet combined with bismuth based quadruple therapy in treatment of peptic ulcer with HP infection can effectively eradicate HP, which has significant clinical efficacy, less drug adverse reactions and high safety.